SUMMARY To determine the clinical implications of HBsAg in severe chronic active liver disease (CALD), patients with HB.Ag positive CALD were compared with those chosen by identical clinical, functional, and morphological criteria in whom this test and anti-HB5 were negative. HB8Ag positive patients were predominantly males over 40 years of age and more frequently failed to respond to conventional treatment programmes with prednisone. HBsAg negative patients were more often female and younger, had a higher incidence of associated immunopathic disease and immunoserological markers in high titre, and more often responded to treatment with full remission of their disease. HBsAg positive patients failing treatment with conventional doses of prednisone often improved with higher doses, but did not reach full remission of their disease. The benefit-risk ratio of both conventional and high doses of prednisone in HBsAg positive severe CALD needs further clarification.
criteria. Differences in sex, age, and incidence of non-organ specific immunoserological markers have been described, but only the predominance of males in HB,Ag positive CALD as opposed to the female predominance in HBsAg negative cases has been a uniform finding. Chronic hepatitis associated with HBsAg has been considered to have a milder course and better prognosis than when the antigen is absent (Sherlock, 1974) . One retrospective report (Dudley et al., 1973) indicates that prednisone therapy in HBsAg positive chronic liver disease is followed by clinical and biochemical improvement, but fails to define a definite therapeutic role of corticosteroids, whereas another (Aronoff et al., 1973) suggests that prednisone and/or azathioprine might have an adverse effect.
We have a treatment programme for patients with severe CALD who differ from those in other series by their homogeneity, particularly with regard to the severity of the liver disease, standardisation of therapies, and regularity of follow-up 
Methods
Postpubertal patients were eligible for our treatment programme if they fulfilled the predetermined criteria of chronicity and activity and had features compatible with CALD on liver biopsy. Chronicity was defined as disease duration of 10 weeks without improvement, or the presence of cirrhosis on liver biopsy. Activity was defined as SGOT elevation x 10 upper limit of normal (N 24 IU/l) or SGOT elevation x 5 in combination with a two-fold or more increase in gamma (N 1 6 g/dl) (Geall et al., 1968; Soloway et al., 1972) . Histological features included chronic active ('aggressive') hepatitis (de Groote et al., 1968) ; subacute hepatitis, characterised by bridging or multilobular necrosis; or cirrhosis with active hepatitis . Coded biopsies were interpreted by the same observer, who also recorded the presence and degree of features consistent with viral hepatitis (acidophilic cell necrosis, cell ballooning, lobular disarray, and Kupffer cell hyperplasia). Alcoholic liver disease, primary biliary cirrhosis, Wilson's disease, druginduced liver disease, and other conditions were excluded by appropriate methods.
One hundred and thirty-six patients who were randomised to different therapies form the basis of the current report. Treatments Summerskill et al., 1975) comprised maintenance doses of prednisone (20 mg daily), prednisone (10 mg daily) together with azathioprine (50 mg daily) or prednisone given on alternate days in doses sufficient to suppress abnormal liver function tests (mean 20 mg on alternate days; range 10-50 mg). In all instances, higher doses of prednisone were given initially. In addition, some patients had been randomised to azathioprine (100 mg daily) or placebo until 1971, when these were discontinued because of inferior results .
Patients were seen at six month intervals, when standardised clinical, biochemical, immunoserological, and histological evaluation was performed. Results of treatment comprised clinical and biochemical resolution; full (histological) remission; treatment failure and death .
Clinical and biochemical resolution comprised absence of symptoms, return of the patient to customary activities, and normal results of standard liver function tests, apart from a two-fold elevation of SGOT. Full remission, in addition to these features, required disappearance from the liver biopsy of histological features of disease activity, the appearances being normal or those ofnon-specific (identical with chronic persistent) hepatitis. Treatment failure was defined as the onset of hepatic coma, the development of ascites, increasing jaundice (serum bilirubin 66 % above the lowest previous level and above 4 mg %) or a 66 % increase in SGOT above the lowest previous value during treatment.
HBsAg was sought in initial and serial six month serum samples (stored at -10°C) by radioimmunoassay (Ausria II Abbott) (Ling and Overby, 1972) ; the passive hemagglutination test (Vyas and Shulman, 1970) and, later, a radioimmunoassay (Ausab, Abbott) (Peterson et al., 1973) were used for detection of anti-HB.. These measurements, as well as other biochemical and immunoserological determinations, were made in laboratories unaware of the diagnosis.
Eighteen patients had HBsAg detected in their serum on at least one occasion and six patients had anti-HBs; 112 patients were repeatedly negative for HB8Ag and anti-HBs. All patients except one were North American Caucasians without a history of drug addiction. HBsAg positive patients were compared with HB8Ag and anti-HBs negative patients for clinical, biochemical, immunoserological, and histological variables, and response to treatment. Statistical analyses were done by chi-square analysis or Fisher's exact test, for dichotomous variables, and by Wilcoxon rank sum tests for continuous variables. Because of possible interrelationships between the variables under study, linear discrimination methods were subsequently used to select that subset of variables which best contributed to discrimination between the HBsAg positive and negative patients. The variables employed were age, sex, SGOT, bilirubin, prothrombin time, serum albumin, serum gamma globulin, presence of associated immunopathic disease, and immunoserology.
Survival curves were calculated by the product limit method (Kaplan and Meier, 1958) . Since major differences in sex, age, and immunoserology were found between the groups, the responses to treatment in the HB.Ag positive group were also compared with that of HBsAg negative groups of similar size, matched for histology, treatment group, sex, age, and immunoserology. Matching was done by an independent observer and by computer. Statistical evaluation was done by the use of Cochran's test for matched pairs (Cochran, 1950) .
Results
ENTRY FEATURES: ALL PATIENTS (Table 1) HBsAg positive patients showed a predominance of (50) 59 (53) 5 (28) 23 (21) 7 (39) 45 (40 Initial responses of patients to higher (60 mg daily) doses of prednisone or of the combination (prednisone 30 mg and azathioprine 50 mg daily) were usually as favourable as in HB.Ag negative patients, although two HBsAg positive patients died during the first month of treatment. However, when doses were reduced to our conventional maintenance levels by a standardised procedure , biochemical deterioration followed in six of 11 (54 % surviving HBsAg positive patients) but occurred in only one of 13 (8%) of HBsAg negative patients (Fig. 1) . Reinstitution of (Sherlock, 1974 
